论文部分内容阅读
目的观察小剂量顺铂注射液联合卡铂注射液化疗同步放疗对晚期声门型喉癌治疗的临床疗效和安全性。方法 52例晚期声门型喉癌患者随机分成对照组26例和试验组26例。2组均给予化疗。对照组患者每周第1~3天静脉滴注顺铂25 mg·m~(-2);试验组第1周的第1~3天静脉滴注顺铂25 mg·m~(-2),第2周的第1~3天静脉滴注卡铂200 mg·m~(-2),第3,4周重复给药,2组均28 d为1个周期,共治疗4个周期。治疗后,观察2组患者的临床疗效和药物不良反应发生情况。结果治疗后,试验组总有效率为65.38%(17/26例),对照组为46.15%(12/26例),差异有统计学意义(P<0.05)。对照组的Ⅲ~Ⅳ度胃肠道反应发生率为84.61%(22/26例),试验组为26.92%(7/26例),差异有统计学意义(P<0.05)。对照组的Ⅲ~Ⅳ度血小板减少发生率为46.15%(12/26例),试验组为76.92%(20/26例),差异有统计学意义(P<0.05);对照组Ⅲ~Ⅳ度血红蛋白减少的发生率为57.69%(15/26例),试验组为61.54%(16/26例),差异无统计学意义(P>0.05);对照组Ⅲ~Ⅳ度脱发的发生率为65.38%(17/26例),试验组为57.69%(15/26例),差异无统计学意义(P>0.05)。结论小剂量顺铂联合卡铂治疗晚期声门型喉癌疗效较好,胃肠道反应发生率较低。
Objective To observe the clinical efficacy and safety of low-dose cisplatin injection combined with carboplatin injection in the treatment of advanced glottic laryngeal cancer with concurrent radiotherapy. Methods 52 patients with advanced glottic cancer were randomly divided into control group (26 cases) and experimental group (26 cases). 2 groups were given chemotherapy. Patients in the control group were given cisplatin 25 mg · m -2 intravenously every day from the first day to the third day, , Carboplatin 200 mg · m ~ (-2) was intravenously dripped on the first to third days of the second week, and repeated on the third and fourth week. Both groups were given 28 cycles of one cycle for a total of 4 cycles. After treatment, the clinical efficacy and adverse drug reactions in two groups were observed. Results After treatment, the total effective rate was 65.38% (17/26 cases) in the experimental group and 46.15% (12/26 cases) in the control group, the difference was statistically significant (P <0.05). The incidence of Ⅲ ~ Ⅳ gastrointestinal reactions in control group was 84.61% (22/26 cases), and that in test group was 26.92% (7/26 cases), the difference was statistically significant (P <0.05). The incidence of grade Ⅲ ~ Ⅳ thrombocytopenia in control group was 46.15% (12/26 cases), and in test group was 76.92% (20/26 cases), the difference was statistically significant (P <0.05) The incidence of hemoglobin reduction was 57.69% (15/26 cases), and the experimental group was 61.54% (16/26 cases), the difference was not statistically significant (P> 0.05). The incidence of Ⅲ ~ Ⅳ degree hair loss in control group was 65.38 % (17/26 cases), the experimental group was 57.69% (15/26 cases), the difference was not statistically significant (P> 0.05). Conclusion Low-dose cisplatin combined with carboplatin in the treatment of advanced glottic laryngeal cancer has better curative effect and lower incidence of gastrointestinal reactions.